Hormonal Management for Transfeminine Individuals

Abramowitz, Jessica; Tangpricha, Vin

doi:10.1016/j.cps.2018.03.003

Cited by 7 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This should be initiated in adolescents once they reach their adult dose of estradiol. In the United States, spironolactone is used most commonly (Abramowitz, 2019;Abramowitz & Tangpricha, 2018). Spironolactone inhibits testosterone α secretion, blocks androgen receptor binding, and may also have estrogenic activity (Hembree et al, 2017).…”

Section: Transgender Womenmentioning

confidence: 99%

Pharmacotherapy of Transgender Children and Adolescents

Farrington¹

2021

Journal of Pediatric Surgical Nursing

View full text Add to dashboard Cite

show abstract

Section: Transgender Womenmentioning

confidence: 99%

Pharmacotherapy of Transgender Children and Adolescents

Farrington¹

2021

Journal of Pediatric Surgical Nursing

View full text Add to dashboard Cite

show abstract

“…19 Various forms of fertility preservation exist (i.e., testicular sperm extraction and banking, oocyte harvesting and banking, and ovarian tissue cryoprecipitation) and should be discussed with individuals before starting therapies that may affect fertility. 19,21,22 Feminizing treatments and practices: Hormone therapy for trans women and transfeminine people typically includes an estrogen and antiandrogen (such as spironolactone), and may also include a progestin. Estrogen therapy will induce breast tissue development.…”

Section: Creating a Respectful Health Care Environmentmentioning

confidence: 99%

“…Estrogen therapy will induce breast tissue development. 21,23,24 There is one case report and many anecdotal reports of trans women inducing lactation (see Induced Lactation and Colactation section) and producing human milk. Breast augmentation in trans women may mask inadequate mammary tissue development or result in pressure atrophy of remaining tissue.…”

Section: Creating a Respectful Health Care Environmentmentioning

confidence: 99%

ABM Clinical Protocol #33: Lactation Care for Lesbian, Gay, Bisexual, Transgender, Queer, Questioning, Plus Patients

Ferri

Rosen-Carole

Jackson

et al. 2020

Breastfeeding Medicine

View full text Add to dashboard Cite

A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards of medical care. Variations in treatment may be appropriate according to the needs of an individual patient.

show abstract

“…As stated before, exogenous hormones should be taken for 1 to 2 years in order to maximize growth of native tissue in preparation for surgical augmentation (8). The most common type of exogenous hormone involves 17-β estradiol, which is often taken orally in doses of 2 to 6 mg per day, but anti-androgens and other formulations are also commonly used (14). Exogenous estrogens may be stopped 2-4 weeks preceding surgery to reduce risk of thromboembolism (15).…”

Section: Preoperative Planningmentioning

confidence: 99%

Breast augmentation for transfeminine patients: methods, complications, and outcomes

Bekeny¹,

Zolper²,

Fan³

et al. 2020

Gland Surg

View full text Add to dashboard Cite

Gender-affirming procedures are critical steps in helping transgender patients reach identity actualization and maximal quality of life. Although there are many techniques for gender-affirming care, surgical breast augmentation, or "top surgery," is often cited as the most important-and sometimes onlyprocedure sought by transfeminine patients. Unfortunately, years of individual and systemic prejudice placed barriers between transgender patients and the healthcare providers needed to affirm gender identity. Policy has recently begun to change as research proving the safety, need, and outcomes of breast augmentation in transfeminine patients dismantles long-established systemic inequalities. With this change, more patients are seeking knowledgeable and respectful providers who can address their unique gender-affirming needs.Overall, breast augmentation in transfeminine patients is technically similar to procedures performed in cisgender peers, but with significant considerations. The most common method of augmentation relies on breast implants, since removable prostheses, exogenous hormones, and fat grafting alone often produce unsatisfactory results. Special attention needs to be directed towards anatomic differences in transgender versus cisgender patients in order to achieve optimal size and position of the breast and nippleareolar complex. Complications for transfeminine patients undergoing breast augmentation are rare, and complication rates are equivalent with cisgender peers who pursue similar procedures. Short-and longterm benefits to quality of life have been well-documented. The aim of this review is to give providers the technical knowledge concerning breast augmentation options, pre-surgical evaluation, post-surgical care, and special considerations in transfeminine patients so that provider and patient can have a successful, respectful partnership in reaching gender-affirming goals.

show abstract

Hormonal Management for Transfeminine Individuals

Cited by 7 publications

References 30 publications

Pharmacotherapy of Transgender Children and Adolescents

Pharmacotherapy of Transgender Children and Adolescents

ABM Clinical Protocol #33: Lactation Care for Lesbian, Gay, Bisexual, Transgender, Queer, Questioning, Plus Patients

Breast augmentation for transfeminine patients: methods, complications, and outcomes

Contact Info

Product

Resources

About